One in Two

In this episode we speak to Dr Marilena Hadjidemetriou about her research on nano-omics, which aims to integrate nanotechnology to the ‘world of omics’ as well as proteomic biomarker discovery. We find out how nano-omics is being used to isolate molecular biomarkers that highlight the early stages of cancer in patients, making earlier cancer detection possible.   Marilena’s research profile: https://nanomedicinelab.com/people/marilena-hadjidemetriou/ Nanomedicine lab 2.0: https://nanomedicinelab.com/research/teams/nano-omics/

Show Notes

In this episode we speak to Dr Marilena Hadjidemetriou about her research on nano-omics, which aims to integrate nanotechnology to the ‘world of omics’ as well as proteomic biomarker discovery.
We find out how nano-omics is being used to isolate molecular biomarkers that highlight the early stages of cancer in patients, making earlier cancer detection possible.
 
Marilena’s research profile: https://nanomedicinelab.com/people/marilena-hadjidemetriou/
Nanomedicine lab 2.0: https://nanomedicinelab.com/research/teams/nano-omics/

What is One in Two?

With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.

This cancer research podcast is brought to you by The University of Manchester in partnership with the Manchester Cancer Research Centre (MCRC). In each episode, our cancer researchers discuss the innovations, discoveries and projects that are changing the landscape of early detection.